We are grateful to our colleagues for their interest and thoughtful comments on our Seminar about systemic lupus erythematosus (SLE).1 We appreciate the remarks from Qihe Xu, and Thomas Pabst and ...

Two studies presented at the 2024 American College of Rheumatology (ACR) Annual Meeting revealed that GLP-1 receptor agonists ...

The glucose-lowering and weight-reducing drug class appears to benefit the heart and kidneys in people with lupus and lupus nephritis, independently of glucose-lowering and weight loss.

For severe cases or when organ systems are involved, treatment may include: Immunosuppressive drugs: Medications such as azathioprine, methotrexate, cyclosporine, mycophenolate mofetil, and ...

Moreover, the guidelines endorse a triple immunosuppressive regimen that includes Lupkynis as a primary ... operates as a clinical stage biopharmaceutical company, which engages in the development of ...

DelveInsight's 'Systemic Lupus Erythematosus Pipeline Insight 2024' report provides comprehensive global coverage of pipeline ...

Fate Therapeutics presents promising data on FT819 showing the first patient treated experienced a favorable clinical experience, achieved drug-free clinical remission, and continues on-study.

The company said the patient, an African American-Asian woman diagnosed with lupus nephritis, received fludarabine-free ...

Lupus anticoagulant tests are in vitro coagulation tests that rely on the phospholipids ... No statistically significant ...

Detailed price information for Aurinia Pharm Ord (AUPH-Q) from The Globe and Mail including charting and trades.

Systemic lupus erythematosus is a potentially fatal ... Patients are treated with immunosuppressive drugs. During the past year, four studies have reported ten mutations in UNC93B1, which encodes ...

If antimalarials do not do the trick, your provider may try one of these systemic treatments: An immunosuppressive, such as methotrexate or mycophenolate mofetil (MMF) A systemic retinoid (such as ...